Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

Christian Mölleken, Maike Ahrens, Anders Schlosser, Julia Dietz, Martin Eisenacher, Helmut E Meyer, Wolff Schmiegel, Uffe Holmskov, Christoph Sarrazin, Grith Lykke Sorensen, Barbara Sitek, Thilo Bracht

Research output: Contribution to journalJournal articleResearchpeer-review

130 Downloads (Pure)

Abstract

Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R 2 =0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.

Original languageEnglish
JournalClinical and Molecular Hepatology
Volume25
Issue number1
Pages (from-to)42-51
ISSN2287-2728
DOIs
Publication statusPublished - Mar 2019

Fingerprint

Hepatitis C
Liver
Serum
Hepacivirus
microfibrillar protein
Alanine Transaminase
Immunoassay
Liver Cirrhosis
Albumins
Viruses

Keywords

  • Antiviral agents
  • Biomarkers
  • Chronic
  • Extracellular matrix proteins
  • Hepatitis C
  • Liver cirrhosis

Cite this

Mölleken, Christian ; Ahrens, Maike ; Schlosser, Anders ; Dietz, Julia ; Eisenacher, Martin ; Meyer, Helmut E ; Schmiegel, Wolff ; Holmskov, Uffe ; Sarrazin, Christoph ; Sorensen, Grith Lykke ; Sitek, Barbara ; Bracht, Thilo. / Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. In: Clinical and Molecular Hepatology. 2019 ; Vol. 25, No. 1. pp. 42-51.
@article{1ee867a5b2834e37bde5b7214d827dfe,
title = "Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients",
abstract = "Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R 2 =0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.",
keywords = "Antiviral agents, Biomarkers, Chronic, Extracellular matrix proteins, Hepatitis C, Liver cirrhosis",
author = "Christian M{\"o}lleken and Maike Ahrens and Anders Schlosser and Julia Dietz and Martin Eisenacher and Meyer, {Helmut E} and Wolff Schmiegel and Uffe Holmskov and Christoph Sarrazin and Sorensen, {Grith Lykke} and Barbara Sitek and Thilo Bracht",
year = "2019",
month = "3",
doi = "10.3350/cmh.2018.0029",
language = "English",
volume = "25",
pages = "42--51",
journal = "Clinical and Molecular Hepatology",
issn = "2287-2728",
publisher = "Korean Association for the Study of the Liver",
number = "1",

}

Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients. / Mölleken, Christian; Ahrens, Maike; Schlosser, Anders; Dietz, Julia; Eisenacher, Martin; Meyer, Helmut E; Schmiegel, Wolff; Holmskov, Uffe; Sarrazin, Christoph; Sorensen, Grith Lykke; Sitek, Barbara; Bracht, Thilo.

In: Clinical and Molecular Hepatology, Vol. 25, No. 1, 03.2019, p. 42-51.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Direct-acting antivirals-based therapy decreases hepatic fibrosis serum biomarker microfibrillar-associated protein 4 in hepatitis C patients

AU - Mölleken, Christian

AU - Ahrens, Maike

AU - Schlosser, Anders

AU - Dietz, Julia

AU - Eisenacher, Martin

AU - Meyer, Helmut E

AU - Schmiegel, Wolff

AU - Holmskov, Uffe

AU - Sarrazin, Christoph

AU - Sorensen, Grith Lykke

AU - Sitek, Barbara

AU - Bracht, Thilo

PY - 2019/3

Y1 - 2019/3

N2 - Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R 2 =0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.

AB - Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R 2 =0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.

KW - Antiviral agents

KW - Biomarkers

KW - Chronic

KW - Extracellular matrix proteins

KW - Hepatitis C

KW - Liver cirrhosis

U2 - 10.3350/cmh.2018.0029

DO - 10.3350/cmh.2018.0029

M3 - Journal article

VL - 25

SP - 42

EP - 51

JO - Clinical and Molecular Hepatology

JF - Clinical and Molecular Hepatology

SN - 2287-2728

IS - 1

ER -